Next generation APOBEC3 inhibitors: optimally designed for potency and nuclease stability
Nucleic Acids Research · 20.03.2025 · 53 (6)
DOI: 10.1093/nar/gkaf234 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, online erschienen am 29.03.2025. Verfasst von Adam K Hedger und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biotechnology, UMass Chan Medical School, Worcester, MA 01605, United States. Hauptthemen laut MEDLINE: Enzyme Inhibitors, Cytidine Deaminase. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, PhRMA Foundation, NIGMS NIH HHS.
Abstract (Originalsprache)
APOBEC3 (or A3) enzymes have emerged as potential therapeutic targets due to their role in introducing heterogeneity in viruses and cancer, often leading to drug resistance. Inhibiting these enzymes has remained elusive as initial phosphodiester (PO)-linked DNA-based inhibitors lack cellular stability and potency. We have enhanced both potency and nuclease stability of 2′-deoxyzebularine (dZ) substrate-based oligonucleotide inhibitors targeting two critical A3s: A3A and A3G. While replacing the phosphate backbone with phosphorothioate (PS) linkages increased nuclease stability, fully PS-modified inhibitors lost potency (up to three-fold) due to the structural constraints of the active site. For both enzymes, mixed PO/PS backbones enhanced potency (up to nine-fold), while also vastly improving nuclease resistance. We also strategically introduced 2′-fluoro sugar modifications, creating the first nanomolar inhibitor of A3G-CTD2. With hairpin-structured inhibitors containing optimized PS patterns and locked nucleic acid (LNA) sugar modifications, we characterize the first single-digit nanomolar inhibitor targeting A3A. These extremely potent A3A inhibitors were highly resistant to nuclease degradation and crucially, restricted A3A deamination in cellulo. Overall, our optimally designed A3 oligonucleotide inhibitors show improved potency and stability compared to previous inhibitors targeting these critical enzymes, toward realizing the therapeutic potential of A3 inhibition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biotechnology, UMass Chan Medical School, Worcester, MA 01605, United States.
- RNA Therapeutics Institute, UMass Chan Medical School, Worcester, MA 01605, United States.
- Cancer Innovation Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, United States.
ORCID-Profile: Jonathan K Watts, Hiroshi Matsuo, Celia A Schiffer
Förderung
- NCI NIH HHS
- PhRMA Foundation
- NIGMS NIH HHS
- NIAID NIH HHS
- NIH Office of Intramural Training and Education's
- NCI
- NIH HHS
- NIH
Zitieren
APA
Hedger, A. K., Myint, W., Lee, J. M., Suchenski Loustaunau, D., Balachandran, V., Shaqra, A. M., Kurt Yilmaz, N., Watts, J. K., Matsuo, H., & Schiffer, C. A. (2025). Next generation APOBEC3 inhibitors: optimally designed for potency and nuclease stability. Nucleic Acids Research, 53(6). https://doi.org/10.1093/nar/gkaf234
Vancouver
Hedger AK, Myint W, Lee JM, Suchenski Loustaunau D, Balachandran V, Shaqra AM, et al. Next generation APOBEC3 inhibitors: optimally designed for potency and nuclease stability. Nucleic Acids Research. 2025;53(6). doi:10.1093/nar/gkaf234
BibTeX
@article{Hedger2025,
author = {Hedger, Adam K and Myint, Wazo and Lee, Jeong Min and Suchenski Loustaunau, Diego and Balachandran, Vanivilasini and Shaqra, Ala M and Kurt Yilmaz, Nese and Watts, Jonathan K and Matsuo, Hiroshi and Schiffer, Celia A},
title = {Next generation APOBEC3 inhibitors: optimally designed for potency and nuclease stability},
journal = {Nucleic Acids Research},
year = {2025},
volume = {53},
number = {6},
doi = {10.1093/nar/gkaf234}
}
EUVIMED